PRONTINAL ® - Beclometasone

PRONTINAL ® is a drug based on Beclometasone dipropionate

THERAPEUTIC GROUP: Drugs for obstructive airway disorders

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications PRONTINAL ® - Beclometasone

PRONTINAL ® is indicated in the control of the evolution of asthmatic pathology and other obstructive diseases of the respiratory tract such as allergic and vasomotor rhinitis, inflammation of the nasal cavities and of the rino-pharyngeal tract.

Mechanism of action PRONTINAL ® - Beclomethasone

Beclometasone, the active ingredient of PRONTINAL ®, is a corticosteroid with marked anti-inflammatory activity especially when administered via topical inhalation.

The topical use of the drug in fact allows a selective action on the mucosa of the respiratory tract, determining a reduction of the inflammatory stimulus through the inhibition upstream of the pathway that leads to the synthesis of inflammatory mediators such as prostaglandins, prostacyclines, leukotrienes and thromboxanes.

The control of the inflammatory stimulus has repercussions not only on the mucosal structure, reducing edema and the consequent vasodilation responsible for congestive symptoms, but also on the recruitment and activation of mast cells and circulating basophils, involved in the allergic genesis of asthma .

The dual anti-inflammatory and antiallergic activity of Beclometasone therefore guarantees an effective control of the underlying pathology, determining at the same time a clear improvement in symptoms.

The aforementioned mechanisms of action are also aided by good pharmacokinetic properties, which allow the proportion of corticosteroid absorbed to be first metabolised by the liver and subsequently excreted via the bile and kidneys.

Studies carried out and clinical efficacy

BECLOMETASONE IN THE TREATMENT OF SEASONAL ALLERGIC RHYITES

Curr Med Res Opin. 2013 Oct; 29 (10): 1329-40. doi: 10.1185 / 03007995.2013.821055. Epub 2013 Aug 6.

Work that identifies the optimal and safe amount of Beclometasone in the daily dose of 320 mcg for the treatment of seasonal allergic rhinitis in both adult patients and adolescent patients.

BECLOMETASONE AND VIRAL BRONCHIOLITE

Pediatr Infect Dis J. 2013 Oct 28. [Epub ahead of print]

Study testing the potential efficacy of long-term administration of Beclomethasone during hospitalization in patients with respiratory syncytial virus and subsequent bronchiolitis, unfortunately demonstrating the futility of such treatment in improving prognosis despite good therapeutic safety.

BECLOMETASONE AND THERAPEUTIC COMPLIANCE

Allergy Asthma Proc. 2013 Nov; 34 (6): 527-33. doi: 10.2500 / aap.2013.34.3706.

Study that reveals the excellent compliance of medical devices based on Beclometasone, emphasizing the ease of use and the consequent therapeutic efficacy, derived from the accurate compliance with medical prescriptions.

Method of use and dosage

PRONTINAL ®

Nebulizer suspension of 0.04 gr of Beclometasone dipropionate per 100 ml of suspension.

PRONTINAL ® therapy should be defined and optimized by the physician based on the patient's physiopathological conditions and the severity of his clinical picture.

In general, adults are advised to spray a single-dose container per session 1 or 2 times a day depending on the severity of the complained symptoms.

Warnings PRONTINAL ® - Beclometasone

Before starting therapy with PRONTINAL ® a careful specialist medical examination is required, aimed at ascertaining the patient's general health and the severity of the clinical picture more precisely.

The doctor should also inform the patient of the potential risks of topical corticosteroid-based therapy, so that they can be recognized in a timely manner avoiding an aggravation of the clinical picture.

Particular caution in the administration of PRONTINAL ® should be reserved for patients with renal diseases, diabetes, hypertension, cardiovascular diseases and viral, fungal or tuberculosis infections.

The use of PRONTINAL ®, without clinical necessity, is prohibited in the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to fully characterize the safety profile of Beclometasone for the health of the fetus and infant, it would be appropriate to extend the contraindications to the use of PRONTINAL ® also to pregnancy and the subsequent period of breastfeeding.

Interactions

Although clinical pharmacological interactions have not yet been characterized, it would be advisable to avoid the simultaneous intake of inhibitors or inducers of the cytochromial system in order to avoid the appearance of significant variations in the pharmacokinetic properties of the active ingredient.

Contraindications PRONTINAL ® - Beclometasone

The use of PRONTINAL ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients or to structurally and chemically related molecules, to patients suffering from viral and tuberculous infections and in pregnant and lactating women.

Undesirable effects - Side effects

Therapy with PRONTINAL ® ® could cause the appearance of candidiasis of the mouth and throat, pneumonia, bronchitis, hypokalemia, nasopharyngitis, hoarseness, sinusitis, arthralgia and myalgia.

Fortunately, the incidence of adverse clinical reactions is rarer.